Position in NVS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$15,672
+$397 QoQ
Shares Held
100
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,508
of 1,598 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Westend Capital Management, LLC holds $35,933,368 across 9 Drug Manufacturers - General names. NVS ranks #6 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
17,366 | $20,829,303 | |
| 2 | MRK |
Merck & Co., Inc.
|
112,297 | $14,430,164 | |
| 3 | JNJ |
Johnson & Johnson
|
1,273 | $323,303 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
2,271 | $286,918 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
611 | $35,205 | |
| 6 | NVS |
Novartis AG
This page
|
100 | $15,672 | |
| 7 | PFE |
Pfizer Inc
|
199 | $4,791 | |
| 8 | OGN |
Organon & Co.
|
313 | $4,238 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,672 | 100 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $15,275 | 100 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $13,787 | 100 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $12,824 | 100 | Shares | Sole | 2025-10-17 | |
| 2025-06-30 | $12,101 | 100 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $11,148 | 100 | Shares | Sole | 2025-04-24 | |
| No filing history on record for this holder in this stock. | ||||||